Hideki Sakagami

524 total citations
25 papers, 407 citations indexed

About

Hideki Sakagami is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Organic Chemistry. According to data from OpenAlex, Hideki Sakagami has authored 25 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 8 papers in Organic Chemistry. Recurrent topics in Hideki Sakagami's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (5 papers) and Alkaloids: synthesis and pharmacology (4 papers). Hideki Sakagami is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (5 papers) and Alkaloids: synthesis and pharmacology (4 papers). Hideki Sakagami collaborates with scholars based in Japan. Hideki Sakagami's co-authors include Kunio Ogasawara, Hiroyuki Arai, Junken Aoki, Yasuhiro Natori, Yumiko Natori, Kiyotaka Nishikawa, Yoshiyuki Kakehi, Takashi Kamikubo, Masamichi Mori and Sadao Kuromitsu and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Chemical Communications.

In The Last Decade

Hideki Sakagami

24 papers receiving 394 citations

Peers

Countries citing papers authored by Hideki Sakagami

Since Specialization

Citations

This map shows the geographic impact of Hideki Sakagami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Sakagami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Sakagami more than expected).

Fields of papers citing papers by Hideki Sakagami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Sakagami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Sakagami. The network helps show where Hideki Sakagami may publish in the future.

Co-authorship network of co-authors of Hideki Sakagami

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Sakagami. A scholar is included among the top collaborators of Hideki Sakagami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Sakagami. Hideki Sakagami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression 2019 ·Molecular Cancer Therapeutics ·Hiroaki Tanaka, Hideki Sakagami, Naoki Kaneko, (unknown), Hiroko Yamamoto, (unknown), Masatoshi Yuri, (unknown), Masamichi Mori, Masahiro Takeuchi, Hiroyuki Koshio, Masaaki Hirano, Sadao Kuromitsu	15
2	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma 2019 ·Leukemia Research ·(unknown), Naoki Kaneko, Hideki Sakagami, (unknown), Masashi Hiramoto, (unknown), Masamichi Mori, Hiroyuki Koshio, Masaaki Hirano, Masahiro Takeuchi	3
3	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non–Small Cell Lung Cancer 2018 ·Molecular Cancer Therapeutics ·Toshiyuki Hirano, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Tatsuya Niimi, Shinya Mimasu, Hideki Sakagami, Kenzo Soejima, Tomoko Betsuyaku	31
4	Structure and biological function of ENPP6, a choline-specific glycerophosphodiester-phosphodiesterase 2016 ·Scientific Reports ·(unknown), Kuniyuki Kano, Kazuki Kato, Hiroyuki Takita, Hideki Sakagami, Yasuo Yamamoto, Emiko Mihara, Hirofumi Ueda, (unknown), Hidetoshi Tokuyama, Hiroyuki Arai, Hiroaki Asou, Junichi Takagi, Ryuichiro Ishitani, Hiroshi Nishimasu, Osamu Nureki, Junken Aoki	48
5	Piperidine derivatives as nonprostanoid IP receptor agonists 2016 ·Bioorganic & Medicinal Chemistry Letters ·Ryoji Hayashi, Hideki Sakagami, (unknown), Hiroaki Ito, (unknown), (unknown)	1
6	Abstract 2586: ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models 2015 ·Cancer Research ·(unknown), Hideki Sakagami, Hiroko Yamamoto, (unknown), (unknown), Shinya Mimasu, (unknown), Masamichi Mori, Hiroyuki Koshio, Masaaki Hirano, Sadao Kuromitsu, Masahiro Takeuchi	7
7	The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice 2014 ·Molecular Cancer Therapeutics ·Masamichi Mori, Yoko Ueno, (unknown), Hiroshi Fushiki, Itsuro Shimada, (unknown), Rika Saito, Kenichi Mori, (unknown), Takatoshi Soga, Hideki Sakagami, Takashi Furutani, Hitoshi Doihara, Masafumi Kudoh, Sadao Kuromitsu	49
8	Abstract 1728: ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations 2014 ·Cancer Research ·Hideki Sakagami, (unknown), Hiroko Yamamoto, Hiroaki Tanaka, (unknown), Masamichi Mori, Hiroyuki Koshio, Masatoshi Yuri, Masaaki Hirano, Sadao Kuromitsu	18
9	Abstract 2678: First demonstration of in vivo PET imaging for ALK inhibitor using [11C]ASP3026, a novel brain-permeable type of ALK inhibitor. 2013 ·Cancer Research ·Hiroshi Fushiki, Rika Saito, Makoto Jitsuoka, Itsuro Shimada, (unknown), Hideki Sakagami, (unknown), Akihiro Noda, Yoshihiro Murakami, (unknown), Yoko Ueno, (unknown), Takatoshi Soga, Shintaro Nishimura, Masamichi Mori, Sadao Kuromitsu	2
10	Abstract 918: ASP3026, a selective ALK inhibitor, shows anti-tumor activity in a mouse model xenografted with NCI-H2228 intracranially. 2013 ·Cancer Research ·(unknown), Hiroshi Fushiki, Hideki Sakagami, Yoko Ueno, Masamichi Mori, Itsuro Shimada, (unknown), (unknown), Shintaro Nishimura, Sadao Kuromitsu	1
11	Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model 2012 ·Cancer Research ·Masamichi Mori, Sadao Kuromitsu, Yoko Ueno, Ruriko Tanaka, Itsuro Shimada, (unknown), (unknown), Hideki Sakagami, Hiroshi Fushiki, Rika Saito, Takanori Sengoku	7
12	Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor - 2011 ·Cancer Research ·Sadao Kuromitsu, Masamichi Mori, Itsuro Shimada, (unknown), Nobuaki Shindoh, Takatoshi Soga, Takashi Furutani, (unknown), Hideki Sakagami, (unknown), Yoko Ueno, Rika Saito, Masao Sasamata, Hiroyuki Mano, (unknown)	9
13	Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models. 2011 ·Molecular Cancer Therapeutics ·Sadao Kuromitsu, Masamichi Mori, (unknown), (unknown), Nobuaki Shindoh, Takatoshi Soga, Takashi Furutani, (unknown), Hideki Sakagami, (unknown), Yoko Ueno, Hiroshi Fushiki, Rika Saito, Masao Sasamata, Hiroyuki Mano, (unknown)	15
14	Biochemical and Molecular Characterization of a Novel Choline-specific Glycerophosphodiester Phosphodiesterase Belonging to the Nucleotide Pyrophosphatase/Phosphodiesterase Family 2005 ·Journal of Biological Chemistry ·Hideki Sakagami, Junken Aoki, Yumiko Natori, Kiyotaka Nishikawa, Yoshiyuki Kakehi, Yasuhiro Natori, Hiroyuki Arai	97
15	Diastereocontrolled synthesis of an enantiopure 4,4-disubstituted cyclohex-2-en-ol: a new route to (+)-quebrachamine 2002 ·Tetrahedron Letters ·Takashi Fujimura, (unknown), Hideki Sakagami, Takahiko Taniguchi, Kunio Ogasawara	8
16	Diastereocontrolled Synthesis of Enantiopure trans- and cis-5-Allylprolinols via a Ring-Contraction Protocol 2001 ·Synlett ·Hideki Sakagami, Kunio Ogasawara	7
17	Cascading Single-step Stereoselective Construction of the α-Alloyohimbine Framework: A New Synthesis of (-)-Nitraraine 2001 ·Heterocycles ·Kunio Ogasawara, Hideki Sakagami	9
18	Lipase-Mediated Synthesis of Enantiopure N-Carbobenzoxy-3-hydroxy-1,2,3,4-tetrahydro- and N-Carbobenzoxy-3-hydroxy-1,2,3,6-tetrahydropyridines from 3-Hydroxypyridine 2000 ·Synthesis ·Hideki Sakagami, Kunio Ogasawara	8
19	A New Synthesis of Psilocin 1999 ·Heterocycles ·Kunio Ogasawara, Hideki Sakagami	24
20	Novel reduction of 3-hydroxypyridine and its use in the enantioselective synthesis of (+)-pseudoconhydrine and (+)-N-methylpseudoconhydrine 1996 ·Chemical Communications ·Hideki Sakagami, Takashi Kamikubo, Kunio Ogasawara	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact